Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
New Combo Boosts Survival for Triple-Negative Breast Cancer
A meta-analysis of triple-negative breast cancer patients found that adding immunotherapy to chemotherapy improved pathological complete res…
Adding immune checkpoint inhibitors to chemotherapy improves survival and tumor response for triple-negative breast cancer patients.
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…
FDA Approves Keytruda (pembrolizumab) for Treatment of Unresectable or Metastatic Melanoma
FDA approves new drug Keytruda for advanced skin cancer
The FDA has approved Keytruda, a PD-1-blocking antibody, for the treatment of patients with unresectable or metastatic melanoma.
FDA approves Keytruda to treat advanced skin cancer that cannot be removed by surgery or has spread to other parts of the body.
Review synthesizes fungal immune evasion mechanisms and emerging immunotherapies for invasive fungal infections
Review explores how fungi evade immune systems and potential new treatment approaches
A narrative review synthesizes advances in understanding immune evasion by major fungal pathogens and immune dysregulation in immunocompromi…
Fungi like Candida and Aspergillus evade the immune system by hiding or forming biofilms, but new treatments could combine antifungal drugs …
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
Regional motif diversity score in cfDNA predicts pembrolizumab response in head and neck cancer
Can a DNA pattern predict who will heal from head and neck cancer immunotherapy?
A phase II trial in 68 patients with locally advanced, resectable HNSCC found that a regional motif diversity score (rMDS) in cell-free DNA …
A new DNA pattern in blood can reliably predict which head and neck cancer patients will respond to immunotherapy and live longer without th…
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…
Pilot qualitative study explores pathways and acceptability of cash transfers for low-income patients with hypertension or diabetes
Could giving cash to patients with high blood pressure or diabetes help their health?
A pilot RCT qualitative sub-study of 100 low-income Pennsylvania Medicaid patients with hypertension or diabetes explored an unconditional c…
Giving cash to low-income patients with high blood pressure or diabetes helped them cover basic needs, reducing stress and making it easier …
Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
Can a new drug combo help men with advanced prostate cancer?
In a single-arm phase 1b/2 trial of 37 patients with mCRPC, Lu-PSMA-617 plus pembrolizumab achieved a 50% PSA decline in 28 participants (76…
A new drug combo helped 28 of 37 men with advanced prostate cancer cut their PSA levels in half while keeping side effects mostly mild to mo…
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo.
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.